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In this video Q&A, we talk to Professor Carlos Caldas about the identification of breast cancer subtypes through
molecular profiling, and the clinical implications for diagnosis and treatment.Carlos Caldas talks on molecular profiling of
breast cancer
Introduction
Carlos Caldas is a Professor of Cancer Medicine at the
University of Cambridge in the UK, and currently heads
the Breast Cancer Functional Genomics Laboratory at the
Cancer Research UK Cambridge Institute. He is an
Honorary Consultant Medical Oncologist at Addenbrooke’s
Hospital and his research interests are in breast cancer
functional genomics, with the aim to identify novel predict-
ive markers and therapeutic targets. Recently he led a
landmark study classifying breast cancer into 10 different
subtypes, which could revolutionize the way breast cancer
is treated.Edited transcript
1. How is breast cancer currently managed?
The first thing to do is to diagnose breast cancer. In
countries like the UK with screening programs, there is
high awareness of breast cancer and it is often diagnosed
at an early stage. After diagnosis with a biopsy, the can-
cer is usually removed by surgical resection. We try to
use breast-conserving surgery rather than mastectomy
to try to preserve the breast. Most patients undergoing
breast-conserving surgery also have radiotherapy to pre-
vent recurrence. It is then necessary to decide which
adjuvant systemic treatment to give; women are risk
stratified into different groups based on whether they
are going to benefit from adjuvant therapy, particularly
chemotherapy. Two other forms of adjuvant therapy are
used; hormone therapy for women who have estrogenCorrespondence: Carlos.Caldas@cruk.cam.ac.uk
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© 2013 Caldas; licensee BioMed Central Ltd. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the orreceptor positive breast cancer (at least 75% of all breast
cancer), and the monoclonal antibody trastuzumab for
HER2 positive breast cancer (up to 15% of all breast
cancer).
2. What are the problems with current treatments for
breast cancer?
The problems are that any systemic treatment, whether
that is hormone therapy, chemotherapy or the more
targeted monoclonal antibody therapy, carries costs and
has the potential for toxicity and harming the patient.
Therefore, we try to make decisions that are rational and
maximize benefit for women that have higher risk. In the
case of hormone therapy and trastuzumab, we have very
good predictive tests that can help to assess benefit. For
example, we know that women with estrogen receptor
negative breast cancer do not benefit from hormone
therapy, and those with HER2 negative breast cancer do
not benefit from trastuzumab treatment. We therefore
have two tests that are routinely applied in the clinic to
make decisions for these two therapies. It is more
difficult to decide whether to prescribe adjuvant chemo-
therapy because we don’t have any specific tests to tell
us whether it will be effective, and we currently make
decisions based on risk profiling using diagnostic tests
applied in the clinic. The promise of novel tests comes
from molecular characterization of tumors, which will
make these decisions more rational, quantitative and
precise.
3. What have been the major breakthroughs in breast
cancer research over the last couple of years?
Until recently we did a couple of tests to help make deci-
sions on breast cancer management. Major determinants of
prognosis assessed by pathologists are tumor grade, tumor
size and lymph node involvement. Two immunohistochem-
ical tests are then done, one for the estrogen receptor andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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discussed earlier. These tests are done in routine clinical
practice, and it is possible to divide breast cancer into
four groups based on immunohistochemistry:
1. Estrogen receptor positive and HER2 negative
(around 70% of breast cancers)
2. Estrogen receptor and HER2 positive (around 7.5% of
breast cancers)
3. Estrogen receptor negative and HER2 positive
(around 7.5% of breast cancers)
4. Negative for both estrogen receptor and HER2
(the remaining 15% of breast cancers)
What we have now shown with our work is that
breast cancer is at least 10 different diseases, and so
we can be much more precise in risk stratifying, as
well as developing novel therapies and estimating
whether a given treatment is going to be of benefit for
a particular patient.4. How will the findings of your study on breast cancer
subtypes be extended?
Our findings published in Nature in 2012 clearly show
that breast cancer is 10 different diseases. The study
was very robust because the subtypes were identified in
1000 breast cancers and then further confirmed in
another 1000. Since then, The Cancer Genome Atlas
(TCGA) group in America confirmed that they could
also identify these 10 subtypes. Therefore, we now have
robust evidence that these 10 subtypes have different
outcomes, and it is likely that they would benefit from
different forms of treatment. We now need to translate
this into clinical application. My group and others
worldwide are trying to come up with a test that assigns
women to one of the 10 classes upon breast cancer
diagnosis. This work is going to occur over the next
2 or 3 years, and we hope to offer it as a diagnostic test
in the future.5. How will the findings be applied in the clinic?
I think women will be assigned to these 10 different clas-
ses because they all have a very different prognosis. There
are classes where the survival rate is as good as over 90%.
There are other classes where unfortunately the survival
with current therapies is poor. In groups with very good
survival we can start asking whether treatments with toxic
side effects can be withheld because women with very
good prognosis might not benefit from them. On the
other hand, women with very poor prognosis could be
prioritized for trials with new drugs. This is one of the
more obvious clinical applications of this information.6. Have you encountered any ethical issues in your
research into breast cancer genetics?
I think that whenever we do studies involving genetics and
patients’ clinical outcome, we need to be very guarded and
protect the autonomy of the individuals participating in
the studies. We can only recruit participants if they give
appropriate consent. After having protected each patient’s
right to autonomy, we also need to respect their privacy
and their right to not having their information displayed
in public. We have to be very careful that when we report
these studies, personal identifiers are completely removed
from the data that is publicly available. Proper consenting
means explaining to the participants that we are going to
be obtaining genetic information but also reassuring them
that we will do the utmost to protect their privacy
and anonymize their data, so that people feel confident
continuing to participate in these studies.
7. Where do you think breast cancer stands in terms of
patient-tailored therapy in comparison with other types
of cancer?
I think that it depends on how you look at it. Being a very
common malignancy, we already use predictive tests
routinely in breast cancer. As I explained earlier, we do
the two tests for estrogen receptor and HER2 in the NHS,
which are extremely important in determining treatments
with hormone therapy and trastuzumab, respectively.
Where we are still falling short is in having tests that do
likewise for chemotherapy. At the moment we do not have
tests that can tell us whether or not women will benefit
from chemotherapy, and we clearly need to develop those
tests. We also hope to develop tests to tell us if all current
treatments are going to be of real benefit, and to show
which patients should be prioritized for studies of novel
compounds. I think that this is where breast cancer stands
at the moment; there is lots of advance on one hand but
also lots of work to do on the other.
8. Where can I find out more?
See reference list [1-9]
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